Biosearch’s Hereditum probiotic strains have been selected from among hundreds of strains found in breastmilk for their outstanding abilities and scientifically proven beneficial effects.
The World Health Organization recommends breastfeeding exclusively for the first six months of a baby’s life, due to the health benefits both in the short and long term. The first medical cause of early cessation of this practice is mastitis, which is usually treated with antibiotics and normally results in mothers deciding to stop breastfeeding.
The Hereditum strain Lactobacillus fermentum LC40 has shown in clinical trials that it not only eliminates the painful symptoms associated with mastitis but it also allows to continue breastfeeding with many benefits for both the mother’s and the baby's health.
The signing of this contract confirms Biosearch Life's leading position in the probiotic market, bringing it closer to the goal of becoming an international benchmark with its range of products in the women's health sector.
Nestlé, with Head Office in Vevey (Switzerland), was founded in 1866 by Henri Nestlé and is currently the world leader in nutrition, health and wellness. It has over 2000 brands, many of them global icons and it is present in 191 countries around the world.
Biosearch Life provides innovation in healthy and natural ingredients integrating its research, development, production and marketing skills around three product platforms: omega-3 (Eupoly-3), probiotics (Hereditum), and botanical extracts (Exxentia).
The company provides comprehensive solutions to clients in over thirty countries seeking maximum satisfaction with customized solutions and a strong portfolio of over 200 products. The company strategy is based on constant innovation. Infant nutrition, functional dairy products and women's health are the sectors in which the company wishes to be a point of reference.